Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Asthma Biologics Market Predicted to Reach USD 19.2 billion by 2031, Growing at a 12.5% CAGR | Exclusive Report by Transparency Market Research

This image opens in the lightbox

News provided by

Transparency Market Research

23 Oct, 2023, 09:18 GMT

Share this article

Share toX

Share this article

Share toX

Asthma biologics are revolutionizing the treatment of severe asthma, offering targeted therapies that address underlying inflammation and improve patients' quality of life.

WILMINGTON, Del., Oct. 23, 2023 /PRNewswire/ -- The asthma biologics market was estimated to have acquired US$ 6.5 billion in 2022.  It is anticipated to register a 12.5% CAGR from 2022 to 2031, and by 2031, the market is likely to gain US$ 19.2 billion.

Asthma biologics are shifting towards personalized treatment regimens. With advances in biomarker identification, physicians can better match patients with the right biologic therapy. This tailoring of treatment can lead to improved efficacy and reduced side effects, opening doors for further research and development in this area.

Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85819 

Asthma Biologics Market Report Scope:

Report Coverage

Details 

Forecast Period 

2023-2031

Base Year 

2017-2020

Size in 2022

US$ 6.5 Bn

Forecast (Value) in 2031

More than US$ 19.2 Bn

Growth Rate (CAGR)

12.5 %

No. of Pages

148 Pages

Segments covered

Drug Class, Distribution Channel

While most of the focus has been on adult patients, there is a growing realization that pediatric asthma represents an underserved market. Developing biologics specifically for children and adolescents could address this gap and create new revenue streams for pharmaceutical companies.

The rise of telemedicine and digital health platforms offers a unique opportunity to monitor asthma patients remotely, gather real time data, and tailor treatment plans accordingly. These technologies can complement biologics and improve patient adherence, creating a niche for innovative solutions in the market.

Key Findings of the Market Report

  • Interleukin Inhibitors are currently the dominating drug class in the asthma biologics market, revolutionizing treatment for severe asthma.
  • Retail Pharmacies dominate the distribution channel in the asthma biologics market due to accessibility and patient-pharmacist interaction.
  • North America leads the asthma biologics market, driven by advanced healthcare infrastructure, robust research, and high asthma prevalence.

Market Trends for Asthma Biologics

  • Asthma biologics are increasingly tailored to individual patient profiles, improving effectiveness and minimizing side effects.
  • The market is expanding to address pediatric asthma, recognizing an underserved demographic.
  • Emerging biologics target non allergic asthma, addressing a substantial patient group.
  • Digital health platforms and telemedicine are integrated for remote patient monitoring, data gathering, and personalized treatment planning.
  • Developing regions in Asia Pacific and Middle East & Africa are witnessing market growth, driven by increasing asthma prevalence and healthcare investments.

Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=85819 

Global Market for Asthma Biologics: Regional Outlook

  • The asthma biologics market in North America is a dynamic landscape. It is dominated by the United States, where high asthma prevalence, advanced healthcare infrastructure, and substantial R&D investments drive market growth.
  • Europe asthma biologics market is thriving, with the United Kingdom, Germany, and France at the forefront. The region benefits from a robust healthcare system and rising asthma incidence. Personalized medicine is a growing trend, with biologics targeting specific patient profiles.
  • Regulatory agencies like the European Medicines Agency (EMA) ensure high quality standards, fostering innovation. The European market also experiences expansion into non-allergic asthma treatments, emphasizing a holistic approach to asthma management.
  • The Asia Pacific asthma biologics market is evolving rapidly fueled by the surging asthma rates and increased healthcare spending. Countries like Japan, China, and India are key players. The region is focused on pediatric asthma treatments and telemedicine integration, harnessing digital health for better patient care.
  • The market has vast potential, which is attractive to both established pharmaceutical companies and emerging startups. As biologics gain traction, they address the unique healthcare challenges of diverse Asian populations.

Global Asthma Biologics Market: Key Players

The competitive landscape of the asthma biologics market is dynamic and marked by both established pharmaceutical giants and innovative biotech companies. Key players like AstraZeneca, GlaxoSmithKline, and Novartis dominate with well established biologics.

Newer entrants such as Regeneron and Teva Pharmaceuticals challenge the status quo with innovative therapies. Collaboration between companies and academic institutions for research and development is common, fostering innovation.

The market is intensively regulated, ensuring the highest standards for product quality and safety. As personalized medicine gains prominence, competition centers on developing biologics that target specific patient profiles and offer enhanced efficacy and fewer side effects.The following companies are well-known participants in the global Asthma Biologics market:

  • Amgen, Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • GSK plc
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Other Prominent Players

Product Portfolio

  • Amgen, Inc. is renowned for its innovative biopharmaceutical products, focusing on breakthroughs in areas such as oncology, bone health, and cardiovascular disease.
  • AstraZeneca is a global leader in pharmaceuticals, specializing in respiratory, cardiovascular, and oncology medications. They are at the forefront of advanced science and technology.

Global Asthma Biologics Market Segmentation 

Drug Class

  • Selective Immuno-suppressants
  • Interleukin Inhibitors
  • Others

Distribution Channel

  • Retail Pharmacies
  • E-commerce
  • Others

Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Place an Order Copy of Asthma Biologics Market Report at:  https://www.transparencymarketresearch.com/checkout.php?rep_id=85819&ltype=S 

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com    
Blog: https://tmrblog.com    
Email: sales@transparencymarketresearch.com 

Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

Modal title

Also from this source

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Ultra-high Purity Anhydrous Hydrogen Chloride (HCl) Gas Market to Reach USD 5.7 Billion by 2031, Expanding at a CAGR of 5.4% | TMR Report

Over the last year, several companies have announced new semiconductor fabrication sites, especially in the U.S., India, and Europe. These...

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

Silicon Metal Market Size Projected to Expand to USD 10.7 Billion by 2031 Exhibiting 5.1% CAGR: Transparency Market Research, Inc.

The market was valued at US$ 6.9 billion in 2022. The Silicon Metal Market Growth is estimated to reach US$ 10.7 billion by the end of 2031,...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.